These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26663620)

  • 21. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial.
    Senat MV; Porcher R; Winer N; Vayssière C; Deruelle P; Capelle M; Bretelle F; Perrotin F; Laurent Y; Connan L; Langer B; Mantel A; Azimi S; Rozenberg P;
    Am J Obstet Gynecol; 2013 Mar; 208(3):194.e1-8. PubMed ID: 23433324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
    Mackeen AD; Rafael TJ; Zavodnick J; Berghella V
    Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM; Istwan NB; Palmer B; Stanziano GJ
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.
    Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Thom EA; Spong CY; Varner M; Malone F; Iams JD; Mercer BM; Thorp J; Sorokin Y; Carpenter M; Lo J; Ramin S; Harper M; Anderson G;
    N Engl J Med; 2007 Aug; 357(5):454-61. PubMed ID: 17671253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
    Rozenberg P; Chauveaud A; Deruelle P; Capelle M; Winer N; Desbrière R; Perrotin F; Bohec C; Connan L; Vayssière C; Langer B; Mantel A; Azimi S; Porcher R; Azria E;
    Am J Obstet Gynecol; 2012 Mar; 206(3):206.e1-9. PubMed ID: 22381603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo.
    Klebanoff MA; Meis PJ; Dombrowski MP; Zhao Y; Moawad AH; Northen A; Sibai BM; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Leveno KJ; Miodovnik M; Conway D; Wapner RJ; Carpenter M; Mercer BM; Ramin SM; Thorp JM; Peaceman AM;
    Am J Obstet Gynecol; 2008 Nov; 199(5):506.e1-7. PubMed ID: 18456237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
    Saghafi N; Khadem N; Mohajeri T; Shakeri MT
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial.
    Combs CA; Garite T; Maurel K; Das A; Porto M;
    Am J Obstet Gynecol; 2011 Mar; 204(3):221.e1-8. PubMed ID: 21376161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
    Coleman S; Wallace L; Alexander J; Istwan N
    J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.
    Grobman WA; Thom EA; Spong CY; Iams JD; Saade GR; Mercer BM; Tita AT; Rouse DJ; Sorokin Y; Wapner RJ; Leveno KJ; Blackwell S; Esplin MS; Tolosa JE; Thorp JM; Caritis SN; Van Dorsten JP;
    Am J Obstet Gynecol; 2012 Nov; 207(5):390.e1-8. PubMed ID: 23010094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 17-alpha hydroxyprogesterone caproate for the prevention of recurrent preterm birth among singleton pregnant women with a prior history of preterm birth: a systematic review and meta-analysis of six randomized controlled trials.
    Baradwan S; Abdulghani SH; Abuzaid M; Khadawardi K; Alshahrani MS; Al-Matary A; AlRasheed MA; Miski NT; Abdulhalim A; Alturki YM; Abu-Zaid A
    Obstet Gynecol Sci; 2021 Nov; 64(6):484-495. PubMed ID: 34670064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
    Stringer EM; Vladutiu CJ; Manuck T; Verbiest S; Ollendorff A; Stringer JS; Menard MK
    Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17-hydroxyprogesterone caproate.
    Combs CA; Garite TJ; Maurel K; Das A;
    Am J Perinatol; 2014 Dec; 31(12):1023-30. PubMed ID: 24566755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.
    Gyamfi C; Horton AL; Momirova V; Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Meis PJ; Spong CY; Dombrowski M; Sibai B; Varner MW; Iams JD; Mercer BM; Carpenter MW; Lo J; Ramin SM; O'Sullivan MJ; Miodovnik M; Conway D;
    Am J Obstet Gynecol; 2009 Oct; 201(4):392.e1-5. PubMed ID: 19716543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
    Feghali M; Venkataramanan R; Caritis S
    Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage.
    Rafael TJ; Mackeen AD; Berghella V
    Am J Perinatol; 2011 May; 28(5):389-94. PubMed ID: 21380984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials.
    Saccone G; Schoen C; Franasiak JM; Scott RT; Berghella V
    Fertil Steril; 2017 Feb; 107(2):430-438.e3. PubMed ID: 27887710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.